If you have been reading about melanotan-2 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
=== Post-translational modifications === Most programs available for protein analysis are not written for proteins that have undergone post-translational modifications. Some programs will accept post-translational modifications to aid in protein identification but then ignore the modification during further protein analysis. It is important to account for these modifications since they can affect the protein's structure. In turn, computational analysis of post-translational modifications has gained the attention of the scientific community. The current post-translational modification programs are only predictive. Chemists, biologists and computer scientists are working together to create and introduce new pipelines that allow for analysis of post-translational modifications that have been experimentally identified for their effect on the protein's structure and function.
In Massachusetts, 57 children with developmental disorders were given oatmeal with radioactive markers. These radiation experiments were not stopped until 1993 under President Bill Clinton. But the injustice committed was not atoned for. For years, uranium hexafluoride caused radiation damage at a DuPont Company plant and to local residents. At times, the plant even deliberately released uranium hexafluoride in its heated gaseous state into the surrounding area to study the effects of the radioactive and chemically aggressive gas.
roeperi grows are not monocultures and other fungi, particularly yeasts, can often be found within and even seem to exceed the density of A. roeperi during certain seasons (for example, in the winter, when adult beetles remain dormant until their springtime emergence). It has been suggested that during the height of a beetle attack, the presence of ethanol – produced by stressed trees and sometimes even by the fungus itself – helps to select for the proliferation of A. roeperi over potential competitors such as molds, which are unable to effectively detoxify this compound. The distribution of A. roeperi mirrors that of its insect partner and is thus quite expansive, both in terms of hosts and geographic range. X. crassiusculus has been reported feeding on woody plants from over 40 families, though it seems to prefer non-coniferous species (with the exception of cedars, from which infestations have been reported). Perhaps in part due to its capacity for extreme polyphagy, this beetle is highly invasive and has spread beyond its native range in southeast Asia to Africa (from tropical regions to the southern tip), Australia and New Zealand, Europe, South America, and the United States, taking A. roeperi with it.
== Pharmaceuticals == The first three nonbenzodiazepine drugs to enter the market were the "Z-drugs": zopiclone, zolpidem and zaleplon. Initially thought to compared to the benzodiazepines, have less of a tendency to induce physical dependence and addiction, although these issues can still become a problem. This has led to the Z-drugs becoming widely prescribed for the treatment of insomnia particularly in elderly patients. Long-term use is not recommended as tolerance and addiction can occur. Zolpidem and zaleplon are, in the US, indicated for 7–10 days of use only. Longer periods of use lead to loss of efficacy from tolerance. Tolerance has also been demonstrated with zopiclone, which is indicated for a maximum of 4 weeks of use in New Zealand.
Sources: en.wikipedia.org
NASA developed a solid lubricant coating, PS300, which is deposited by thermal spraying to protect foil air bearings. PS300 lowers friction, reduces emissions, and has been used by NASA in advanced aeropropulsion engines, refrigeration compressors, turbochargers, and hybrid electrical turbogenerators. ADMA Products has found widespread industrial applications for the material.
Div. 1: Single early – with cup-shaped single flowers, no larger than 8 cm (3 inches) across. They bloom early to mid-season. Growing 15 to 45 cm (6 to 18 inches) tall. Div. 2: Double early – with fully double flowers, bowl shaped to 8 cm (3 inches) across. Plants typically grow from 30–40 cm (12–16 inches) tall. Div. 3: Triumph – single, cup shaped flowers up to 6 cm (2.5 inches) wide. Plants grow 35–60 cm (14–24 inches) tall and bloom mid to late season. Div. 4: Darwin hybrid – single flowers are ovoid in shape and up to 6 cm (2.5 inches) wide. Plants grow 50–70 cm (20–28 inches) tall and bloom mid to late season. This group should not be confused with older Darwin tulips, which belong in the Single Late Group below. Div. 5: Single late – cup or goblet-shaped flowers up to 8 cm (3 inches) wide, some plants produce multi-flowering stems. Plants grow 45–75 cm (18–30 inches) tall and bloom late season. Div. 6: Lily-flowered – the flowers possess a distinct narrow 'waist' with pointed and reflexed petals. Previously included with the old Darwins, only became a group in their own right in 1958. Div. 7: Fringed (Crispa) – cup or goblet-shaped blossoms edged with spiked or crystal-like fringes, sometimes called "tulips for touch" because of the temptation to "test" the fringes to see if they are real or made of glass. Perennials with a tendency to naturalise in woodland areas, growing 45–65 cm (18–26 inches) tall and blooming in late season. Div. 8: Viridiflora Div. 9: Rembrandt Div. 10: Parrot Div. 11: Double late – Large, heavy blooms.
In another study, after oxytocin administration, individuals displayed an enhanced ability to recognize expressions of fear compared to those who received the placebo. Oxytocin modulates fear responses by enhancing the maintenance of social memories. Rats who are genetically modified to have a surplus of oxytocin receptors display a greater fear response to a previously conditioned stressor. Oxytocin enhances the aversive social memory, leading the rat to display a greater fear response when the aversive stimulus is encountered again.
However there have not been any in vivo or in vitro studies of magnetic nanoparticles being used to deliver drugs to the arteries to effectively reduce inflammation. Other potential applications of magnetic nanoparticles are brain imaging and drug delivery past the blood-brain barrier (BBB) using biodegradable magnetic iron oxide nanoparticles. The scope of this application is the treatment of central nervous system (CNS) disorders by functioning as contrast agents and drug carriers. To cross the BBB, these nanoparticles are designed by creating specificity to the BBB; this is achieved by designing the surface of the nanoparticles to be engrafted to ligands, antibodies, small molecules, cell-penetrating peptides, or conjugated RNA to target specific receptors situated along the BBB in order to facilitate entry. As opposed to methods of drug delivery that result in drugs being removed from the cerebrospinal fluid (CSF) or being degraded, magnetic nanoparticle delivery presents an opportunity to protect therapeutics as well as encourage more efficient delivery following the introduction of the nanoparticles. Magnetic nanoparticles can also be used in conjunction with imaging modalities like ultrasound to improve imaging. The use of nanoparticles in ophthalmic drug delivery is also being explored in clinical research. Magnetic nanoparticles inserted into rats' corneas or administered in an eye drop solution showed high adhesion to the target site. However, the exact mechanism by which the adhesion occurred is still being researched.
=== The Squibb Institute for Medical Research, New Jersey === Ondetti had multiple obstacles to overcome to work in the US. Primarily, most of Ondetti's English experience had been from chemistry textbooks. Surprisingly, Ondetti's largest language barrier was not Spanish to English, but adjusting from British to American English. Fortunately, he found an English tutor in America. Overall, Ondetti enjoyed his move to America, citing the ease of finding a car and an apartment as examples. The research which Ondetti worked on was also improved. Instead of sending samples to the United States from Argentina, he brought them down the hall. Ondetti was placed in the peptide synthesis research group. As opposed to his initial reaction to carbohydrate chemistry, he was pleased because he enjoyed contact with biologists. Over the next nine years, Ondetti gained recognition in peptide synthesis and the position as peptide chemistry chair. After this promotion, Miguel and his wife, Josephine, definitely decided to stay in America after considering the possibility of moving back during the original move. During the 1960s, peptides were considered valuable drug candidates. Ondetti's group researched synthesis of insulin and venom peptides. In the mid 1960s, the director created a task force to work on peptides. In this rearrangement, Ondetti came to work with Emily Sabo. During Squibb's effort to synthesis secretin, Ondetti stopped carrying a lab notebook. He considered Sabo to be such an accurate and skilled chemist, that he let her do all the experiments.
Sources: en.wikipedia.org
=== Narcotic analgesics === Narcotic analgesics tend to be opioids. They bind to opioid receptors which are G protein-coupled receptors distributed in brain, spinal cord, digestive tract, peripheral neurons.
Relative to 150 mg/day bicalutamide, levels of (R)-bicalutamide are about 15% higher at a dosage of 200 mg/day and about 50% higher at a dosage of 300 mg/day. In contrast to (R)-bicalutamide, the inactive enantiomer (S)-bicalutamide is much more rapidly absorbed (as well as cleared from circulation). Steady-state concentrations of the drug are reached after 4 to 12 weeks of administration independently of dosage, with an approximate 10- to 20-fold progressive accumulation of circulating levels of (R)-bicalutamide. The relatively long time to reach steady-state is a product of the long elimination half-life of bicalutamide. With single 50 mg and 150 mg doses of bicalutamide, mean peak concentrations (Cmax) of (R)-bicalutamide are 0.77 μg/mL (1.8 μmol/L) (at 31 hours) and 1.4 μg/mL (3.3 μmol/L) (at 39 hours), respectively. At steady-state, mean circulating concentrations (Css) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L), respectively. In another 150 mg/day bicalutamide study, mean circulating concentrations of (R)-bicalutamide were 19.4 μg/mL (45.1 μmol/L) and 28.5 μg/mL (66.3 μmol/L) on days 28 and 84 (weeks 4 and 12) of treatment, respectively. There is wide interindividual variability, up to 15.7-fold, in steady-state (R)-bicalutamide levels with bicalutamide therapy. This is the case for all dosage levels of bicalutamide, and ranges in (R)-bicalutamide levels for different dosages show significant overlap.
Artistic Achievement – Inside Audio Achievement – The Last Guardian Best Game – Uncharted 4: A Thief's End British Game – Overcooked Debut Game – Firewatch Evolving Game – Rocket League Family – Overcooked Game Design – Inside Game Innovation – That Dragon, Cancer Mobile – Pokémon Go Multiplayer – Overwatch Music – Virginia Narrative – Inside Original Property – Inside Performer – Cissy Jones (as Delilah, Firewatch) BAFTA Special Award – Brenda Romero BAFTA Special Award - Brandon Beck and Marc Merrill of Riot Games BAFTA Ones to Watch Award – Among the Stones AMD eSports Audience Award – Clash Royale
== Dried blood spot testing for HIV infection == The technology aims to improve diagnostic services to HIV-infected infants and patients, starting treatment, and suppressing the virus from replicating. It is ideal in resource-poor settings due to the samples' longer lifespan with reduced need for refrigeration and the less invasive nature of the test compared with other methods. Unlike ELISA testing for HIV-antibodies in the blood, which may be transmitted to infants in pregnancy independently of the virus itself, dried blood spot testing can be used to detect the genetic material of the actual virus, thereby avoiding the likelihood of a false positive result. DBS specimens also pose less of a biohazard risk to handlers, and are easier to transport or store than liquid blood specimens. Results from DBS correlate with traditional plasma testing, the standard sample. This technology is available in countries with high HIV prevalence, made possible by collaborating with different health organisations and national governments.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.